https://www.selleckchem.com/pr....oducts/crenolanib-cp
The five-year relative survival rate increased from 81% to 92% for men and from 88% to 96% for women. This increase reflected the increasing five-year relative survival rate of patients with stage II, III, and IV. We observed an increase in incidence for patients with stage I and III and an improvement in survival for patients with stage II, III and IV. These trends can be partly explained by the introduction of the SLNB and the novel drugs. We observed an increase in incidence for patients with stage I and III and an impro
Like
Comment
Share
